Teladoc Health (TDOC) News Today

Teladoc Health, Inc. (NYSE: TDOC) shares have decreased as investors weigh mixed earnings-estimate revisions against a new investor investigation.

• Positive Sentiment: Zacks Research improved several profit forecasts. The firm raised its FY2026 EPS estimate to a loss of $0.89 from $0.96 and its FY2027 estimate to a loss of $0.98 from $1.04. Estimates also improved for Q4 2026, Q1–Q3 2027, and Q1 2028, suggesting somewhat better expected profitability than previously projected.
• Neutral Sentiment: The overall outlook remains challenging. Despite the upward revisions, Zacks still expects Teladoc to remain unprofitable through FY2027, with consensus calling for a $0.89-per-share loss in the current year. The firm lowered its Q3 2026 estimate to a $0.21 loss from $0.20 and its Q2 2028 estimate to a $0.21 loss from $0.20, partially offsetting the positive revisions.
• Negative Sentiment: Pomerantz LLP announced an investor investigation into Teladoc. The law firm is seeking information from investors regarding potential claims on behalf of shareholders. Such announcements can pressure a stock by increasing legal and reputational uncertainty, although the investigation does not establish wrongdoing by Teladoc. Pomerantz investor investigation announcement

The estimate changes provide a modestly favorable signal for TDOC’s cost-control and earnings trajectory, but the continued expectation of losses and the investor investigation likely explain why sentiment remains weak. Teladoc’s latest reported quarter also showed revenue declining 4% year over year, reinforcing concerns about growth.